{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:42:22Z","timestamp":1792255342026,"version":"4.4.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06274-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:01:48Z","timestamp":1792213308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotective Role of Withaferin A in Huntington\u2019s Disease: Current Evidence and Future Perspectives"],"prefix":"10.1007","volume":"63","author":[{"given":"Risha","family":"Kumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwan","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralikrishnan","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-0788","authenticated-orcid":false,"given":"Shweta","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"issue":"1","key":"6274_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2021-003074","volume":"22","author":"TB Stoker","year":"2022","unstructured":"Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA (2022) Huntington\u2019s disease: diagnosis and management. Pract Neurol 22(1):32\u201341","journal-title":"Pract Neurol"},{"key":"6274_CR2","unstructured":"Br\u00e1s IC, Dawson J, Kay C, Caron NS, Hayden MR. Huntington disease. Genereviews\u00ae[internet]. 2026;"},{"key":"6274_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28484","author":"R Andhale","year":"2022","unstructured":"Andhale R, Shrivastava D (2022) Huntington\u2019s disease: a clinical review. Cureus. https:\/\/doi.org\/10.7759\/cureus.28484","journal-title":"Cureus"},{"issue":"12","key":"6274_CR4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"A Medina","year":"2022","unstructured":"Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of Huntington\u2019s disease: an updated systematic review and meta-analysis. Mov Disord 37(12):2327\u20132335","journal-title":"Mov Disord"},{"issue":"1","key":"6274_CR5","first-page":"4","volume":"59","author":"B Papanna","year":"2024","unstructured":"Papanna B, Lazzari C, Rabottini M (2024) Huntington\u2019s disease prevalence in Asia: a systematic review and meta-analysis. Riv Psichiatr 59(1):4\u201312","journal-title":"Riv Psichiatr"},{"issue":"Suppl 10","key":"6274_CR6","first-page":"13","volume":"34","author":"B Papanna","year":"2022","unstructured":"Papanna B, Lazzari C, Rabottini M (2022) The prevalence of Huntington disease in asia highlights needs in clinical, genetic and instrumental diagnosis: a systematic review and meta-analysis. Psychiatr Danub 34(Suppl 10):13\u201323","journal-title":"Psychiatr Danub"},{"issue":"8","key":"6274_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s00415-025-13255-1","volume":"272","author":"A Thompson","year":"2025","unstructured":"Thompson A, Quarrell O, Strong M (2025) Variation in the reported prevalence of Huntington\u2019s disease: a systematic review and guide to interpretation. J Neurol 272(8):534","journal-title":"J Neurol"},{"issue":"4","key":"6274_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1515\/medgen-2021-2101","volume":"33","author":"L Arning","year":"2022","unstructured":"Arning L, Nguyen HP (2022) Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. Medizinische Genet 33(4):293\u2013300","journal-title":"Medizinische Genet"},{"key":"6274_CR9","doi-asserted-by":"crossref","unstructured":"Saha G, Ghosh S, Dubey VK, Saudagar P (2022) Gene alterations induced by glutamine (Q) encoding CAG repeats associated with neurodegeneration. Gene, drug, and tissue engineering. Springer, pp 3\u201323","DOI":"10.1007\/978-1-0716-2716-7_1"},{"issue":"6","key":"6274_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/genes15060807","volume":"15","author":"M Pengo","year":"2024","unstructured":"Pengo M, Squitieri F (2024) Beyond CAG repeats: the multifaceted role of genetics in Huntington disease. Genes (Basel) 15(6):807","journal-title":"Genes (Basel)"},{"issue":"1","key":"6274_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JHD-200445","volume":"10","author":"J Donaldson","year":"2021","unstructured":"Donaldson J, Powell S, Rickards N, Holmans P, Jones L (2021) What is the pathogenic CAG expansion length in Huntington\u2019s disease? J Huntingtons Dis 10(1):175\u2013202","journal-title":"J Huntingtons Dis"},{"key":"6274_CR12","doi-asserted-by":"crossref","unstructured":"Murmann AE, Patel M, Jeong SY, Bartom ET, Morton AJ, Peter ME (2022) The length of uninterrupted CAG repeats in stem regions of repeat disease associated hairpins determines the amount of short CAG oligonucleotides that are toxic to cells through RNA interference. Cell Death Dis 13(12):1078","DOI":"10.1038\/s41419-022-05494-1"},{"issue":"5","key":"6274_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00018-022-04280-8","volume":"79","author":"MD Costa","year":"2022","unstructured":"Costa MD, Maciel P (2022) Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets. Cell Mol Life Sci 79(5):274","journal-title":"Cell Mol Life Sci"},{"key":"6274_CR14","unstructured":"Tunal\u0131 NE (2020) Molecular mechanisms of polyglutamine pathology and lessons learned from Huntington\u2019s disease. Neurodegenerative diseases-molecular mechanisms and current therapeutic approaches. IntechOpen"},{"issue":"12","key":"6274_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126789","volume":"25","author":"NS Moldovean-Cioroianu","year":"2024","unstructured":"Moldovean-Cioroianu NS (2024) Reviewing the structure\u2013function paradigm in polyglutamine disorders: a synergistic perspective on theoretical and experimental approaches. Int J Mol Sci 25(12)","journal-title":"Int J Mol Sci"},{"key":"6274_CR16","doi-asserted-by":"publisher","first-page":"769184","DOI":"10.3389\/fmolb.2021.769184","volume":"8","author":"OD Jarosi\u0144ska","year":"2021","unstructured":"Jarosi\u0144ska OD, R\u00fcdiger SGD (2021) Molecular strategies to target protein aggregation in Huntington\u2019s disease. Front Mol Biosci 8:769184","journal-title":"Front Mol Biosci"},{"key":"6274_CR17","doi-asserted-by":"crossref","unstructured":"Qureshi FH, Qureshi SH, Zia T, Khawaja F. Huntington\u2019s disease (HD): a brief review. Eur J Public Heal Stud. 2022;5(1).","DOI":"10.46827\/ejphs.v5i1.115"},{"issue":"1","key":"6274_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42466-023-00285-1","volume":"5","author":"C Saft","year":"2023","unstructured":"Saft C, Burgunder JM, Dose M, Jung HH, Katzenschlager R, Priller J et al (2023) Symptomatic treatment options for Huntington\u2019s disease (guidelines of the German Neurological Society). Neurol Res Pract 5(1):61","journal-title":"Neurol Res Pract"},{"issue":"10","key":"6274_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol 16(10):529\u2013546","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"6274_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","volume":"18","author":"S Upadhayay","year":"2023","unstructured":"Upadhayay S, Jamwal S, Kumar P (2023) Animal models of Huntington\u2019s disease and their applicability to novel drug discovery and development. Expert Opin Drug Discov 18(5):527\u2013538","journal-title":"Expert Opin Drug Discov"},{"issue":"13","key":"6274_CR21","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.3390\/ijms26136220","volume":"26","author":"G Olmedo-Saura","year":"2025","unstructured":"Olmedo-Saura G, Bernardi E, Bojtos L, Mart\u00ednez-Horta S, Pagonabarraga J, Kulisevsky J et al (2025) Update on the symptomatic treatment of Huntington\u2019s disease: from pathophysiology to clinical practice. Int J Mol Sci 26(13):6220","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6274_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13020-023-00745-5","volume":"18","author":"E Hu","year":"2023","unstructured":"Hu E, Li Z, Li T, Yang X, Ding R, Jiang H et al (2023) A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example. Chin Med 18(1):40","journal-title":"Chin Med"},{"issue":"3","key":"6274_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.chnaes.2023.06.009","volume":"44","author":"R Khabiya","year":"2024","unstructured":"Khabiya R, Choudhary GP, Jnanesha AC, Kumar A, Lal RK (2024) An insight into the potential varieties of Ashwagandha (Indian ginseng) for better therapeutic efficacy. Ecol Front 44(3):444\u2013450","journal-title":"Ecol Front"},{"issue":"5","key":"6274_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10522-025-10320-0","volume":"26","author":"M Vittal","year":"2025","unstructured":"Vittal M, Vinciguerra M (2025) Enhancing healthspan with Ashwagandha (Withania somnifera): a comprehensive review of its multifaceted geroprotective benefits. Biogerontology 26(5):179","journal-title":"Biogerontology"},{"key":"6274_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114101","volume":"276","author":"VK Joshi","year":"2021","unstructured":"Joshi VK, Joshi A (2021) Rational use of Ashwagandha in Ayurveda (traditional Indian medicine) for health and healing. J Ethnopharmacol 276","journal-title":"J Ethnopharmacol"},{"key":"6274_CR26","doi-asserted-by":"crossref","unstructured":"Swaroop A (2025) Withaferin A in human health. Ashwagandha. CRC Press, pp 193\u2013202","DOI":"10.1201\/9781032675961-17"},{"issue":"2","key":"6274_CR27","first-page":"115","volume":"43","author":"P Kumar","year":"2024","unstructured":"Kumar P, Banik SP, Goel A, Chakraborty S, Bagchi M, Bagchi D (2024) Revisiting the multifaceted therapeutic potential of Withaferin A (WA), a novel steroidal lactone, W-ferinAmax ashwagandha, from Withania Somnifera (L) Dunal. J Am Nutr Assoc 43(2):115\u2013130","journal-title":"J Am Nutr Assoc"},{"issue":"2","key":"6274_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/1673-5374.290894","volume":"16","author":"N Ram","year":"2021","unstructured":"Ram N, Peak SL, Perez AR, Jinwal UK (2021) Implications of Withaferin A in neurological disorders. Neural Regen Res 16(2):304\u2013305","journal-title":"Neural Regen Res"},{"issue":"12","key":"6274_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/biomedicines8120571","volume":"8","author":"T Behl","year":"2020","unstructured":"Behl T, Sharma A, Sharma L, Sehgal A, Zengin G, Brata R et al (2020) Exploring the multifaceted therapeutic potential of Withaferin A and its derivatives. Biomedicines 8(12):571","journal-title":"Biomedicines"},{"issue":"6","key":"6274_CR30","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/pharmaceutics14061256","volume":"14","author":"AM Alnuqaydan","year":"2022","unstructured":"Alnuqaydan AM, Almutary A, Bhat GR, Mir TA, Wani SI, Rather MY et al (2022) Evaluation of the cytotoxic, anti-inflammatory, and immunomodulatory effects of Withaferin A (WA) against lipopolysaccharide (LPS)-induced inflammation in immune cells derived from BALB\/c mice. Pharmaceutics 14(6):1256","journal-title":"Pharmaceutics"},{"issue":"8","key":"6274_CR31","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1007\/s12035-021-02397-8","volume":"58","author":"T Joshi","year":"2021","unstructured":"Joshi T, Kumar V, Kaznacheyeva EV, Jana NR (2021) Withaferin a induces heat shock response and ameliorates disease progression in a mouse model of Huntington\u2019s disease. Mol Neurobiol 58(8):3992\u20134006","journal-title":"Mol Neurobiol"},{"issue":"2","key":"6274_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020160","volume":"16","author":"S Kumar","year":"2023","unstructured":"Kumar S, Mathew SO, Aharwal RP, Tulli HS, Mohan CD, Sethi G et al (2023) Withaferin A: a pleiotropic anticancer agent from the Indian medicinal plant Withania somnifera (L.) Dunal. Pharmaceuticals (Basel) 16(2)","journal-title":"Pharmaceuticals (Basel)"},{"key":"6274_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975320","volume":"13","author":"M Atteeq","year":"2022","unstructured":"Atteeq M (2022) Evaluating anticancer properties of Withaferin A\u2014a potent phytochemical. Front Pharmacol 13","journal-title":"Front Pharmacol"},{"issue":"1","key":"6274_CR34","doi-asserted-by":"publisher","first-page":"9922626","DOI":"10.1155\/ijfo\/9922626","volume":"2025","author":"SK Singirala","year":"2025","unstructured":"Singirala SK, Dubey PK, Roy S (2025) Extraction of bioactive compounds from Withania somnifera: the biological activities and potential application in the food industry: a review. Int J Food Sci 2025(1):9922626","journal-title":"Int J Food Sci"},{"issue":"16","key":"6274_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/15287394.2022.2071787","volume":"85","author":"A Rossato Viana","year":"2022","unstructured":"Rossato Viana A, Godoy Noro B, Lenz JC, Luiza Machado Teixeira M, Bolson Serafin M, H\u00f6rner R et al (2022) Cytotoxic screening and antibacterial activity of Withaferin A. J Toxicol Environ Health A 85(16):685\u2013698","journal-title":"J Toxicol Environ Health A"},{"issue":"24","key":"6274_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26247696","volume":"26","author":"T Sultana","year":"2021","unstructured":"Sultana T, Okla MK, Ahmed M, Akhtar N, Al-Hashimi A, Abdelgawad H et al (2021) Withaferin A: from ancient remedy to potential drug candidate. Molecules 26(24)","journal-title":"Molecules"},{"issue":"1","key":"6274_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13048-020-00684-x","volume":"13","author":"AR Straughn","year":"2020","unstructured":"Straughn AR, Kakar SS (2020) Withaferin A: a potential therapeutic agent against COVID-19 infection. J Ovarian Res 13(1):79","journal-title":"J Ovarian Res"},{"issue":"4","key":"6274_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7324\/JAPS.2021.110402","volume":"11","author":"M Dhawan","year":"2021","unstructured":"Dhawan M, Parmar M, Sharun K, Tiwari R, Bilal M, Dhama K (2021) Medicinal and therapeutic potential of withanolides from Withania somnifera against COVID-19. J Appl Pharm Sci 11(4):6\u201313","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"6274_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1775704","volume":"40","author":"V Kumar","year":"2022","unstructured":"Kumar V, Dhanjal JK, Bhargava P, Kaul A, Wang J, Zhang H et al (2022) Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J Biomol Struct Dyn 40(1):1\u201313","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"6274_CR40","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00210-024-03662-y","volume":"398","author":"MF Nisar","year":"2025","unstructured":"Nisar MF, Wan C, B\u00fcsselberg D, Calina D, Sharifi-Rad J (2025) Current mechanistic insights into Withaferin A: a promising potential adjuvant anticancer agent from Withania somnifera. Naunyn Schmiedebergs Arch Pharmacol 398(4):3573\u20133593","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"17","key":"6274_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173090","volume":"16","author":"R Wadhwa","year":"2024","unstructured":"Wadhwa R, Wang J, Shefrin S, Zhang H, Sundar D, Kaul SC (2024) Molecular insights into the anticancer activity of withaferin-A: the inhibition of survivin signaling. Cancers (Basel) 16(17)","journal-title":"Cancers (Basel)"},{"key":"6274_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2024.109439","volume":"207","author":"L Bouissane","year":"2024","unstructured":"Bouissane L, Bailly C (2024) Withania frutescens (L.) Pauquy, a valuable Mediterranean shrub containing bioactive withanolides. Steroids 207","journal-title":"Steroids"},{"key":"6274_CR43","doi-asserted-by":"publisher","DOI":"10.1201\/9781003186274","volume-title":"Phytochemistry of Withania somnifera","author":"B Kumar","year":"2021","unstructured":"Kumar B, Bajpai V, Gond V, Tiwari S, Madhusudanan KP (2021) Phytochemistry of Withania somnifera. CRC Press"},{"issue":"4","key":"6274_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s42452-024-05845-x","volume":"6","author":"FZ Ozeer","year":"2024","unstructured":"Ozeer FZ, Nagandran S, Wu YS, Wong LS, Stephen A, Lee MF et al (2024) A comprehensive review of phytochemicals of Withania somnifera (L.) Dunal (Solanaceae) as antiviral therapeutics. Discov Appl Sci 6(4):187","journal-title":"Discov Appl Sci"},{"issue":"6","key":"6274_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/plants11060767","volume":"11","author":"JW Ha","year":"2022","unstructured":"Ha JW, Yu JS, Lee BS, Kang DM, Ahn MJ, Kim JK et al (2022) Structural characterization of withanolide glycosides from the roots of Withania somnifera and their potential biological activities. Plants 11(6):767","journal-title":"Plants"},{"issue":"2","key":"6274_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/2213240607999200813194349","volume":"7","author":"B Antony","year":"2020","unstructured":"Antony B, Benny M, Kuruvilla BT, Sebastian A, Aravindakshan Pillai AA, Joseph B et al (2020) Development and validation of an RP-HPLC method for the simultaneous determination of total withanolide glycosides and Withaferin A in Withania somnifera (Ashwagandha). Curr Chromatogr 7(2):106\u2013120","journal-title":"Curr Chromatogr"},{"issue":"3","key":"6274_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00894-021-04703-6","volume":"27","author":"A Ghosh","year":"2021","unstructured":"Ghosh A, Chakraborty M, Chandra A, Alam MP (2021) Structure-activity relationship (SAR) and molecular dynamics study of Withaferin-A fragment derivatives as potential therapeutic lead against main protease (Mpro) of SARS-CoV-2. J Mol Model 27(3):97","journal-title":"J Mol Model"},{"key":"6274_CR48","unstructured":"Villagomez R, Vila JL, Bravo JA. Pictorial mechanistic views on the chemical history of Withaferin A: the structural determination of the side chain, the organic chemistry notebook series, a didactical approach, No 16. Rev Bol Quim. 2022;46\u201361."},{"key":"6274_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8985179","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Ayatollahi SA, Kobarfard F, Staniak M, St\u0119pie\u0144 A et al (2021) Chemical composition, biological activity, and health\u2010promoting effects of Withania somnifera for pharma\u2010food industry applications. J Food Qual. https:\/\/doi.org\/10.1155\/2021\/8985179","journal-title":"J Food Qual"},{"key":"6274_CR50","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.toxrep.2022.05.012","volume":"9","author":"SK Gupta","year":"2022","unstructured":"Gupta SK, Jadhav S, Gohil D, Panigrahi GC, Kaushal RK, Gandhi K et al (2022) Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice. Toxicol Rep 9:1204\u20131212","journal-title":"Toxicol Rep"},{"issue":"1","key":"6274_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaim.2018.12.008","volume":"11","author":"N Pires","year":"2020","unstructured":"Pires N, Gota V, Gulia A, Hingorani L, Agarwal M, Puri A (2020) Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: a phase I trial. J Ayurveda Integr Med 11(1):68\u201372","journal-title":"J Ayurveda Integr Med"},{"issue":"12","key":"6274_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26123696","volume":"26","author":"R Das","year":"2021","unstructured":"Das R, Rauf A, Akhter S, Islam MN, Emran TB, Mitra S et al (2021) Role of withaferin A and its derivatives in the management of Alzheimer\u2019s disease: recent trends and future perspectives. Molecules 26(12)","journal-title":"Molecules"},{"issue":"1","key":"6274_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90181-y","volume":"11","author":"K Kumano","year":"2021","unstructured":"Kumano K, Kanak MA, Saravanan PB, Blanck JP, Liu Y, Vasu S et al (2021) Withaferin A inhibits lymphocyte proliferation, dendritic cell maturation in vitro and prolongs islet allograft survival. Sci Rep 11(1)","journal-title":"Sci Rep"},{"issue":"1","key":"6274_CR54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12906-021-03373-4","volume":"21","author":"MA Islam","year":"2021","unstructured":"Islam MA, Zaman S, Biswas K, Al-Amin MY, Hasan MK, Alam A et al (2021) Evaluation of cholinesterase inhibitory and antioxidant activity of Wedelia chinensis and isolation of apigenin as an active compound. BMC Complement Med Ther 21(1):204","journal-title":"BMC Complement Med Ther"},{"issue":"6","key":"6274_CR55","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/ph18060816","volume":"18","author":"L Yang","year":"2025","unstructured":"Yang L, Zou Y, Fan J, Yin P, Qin H, Li Z et al (2025) Withaferin A rescues brain network dysfunction and cognitive deficits in a mouse model of Alzheimer\u2019s disease. Pharmaceuticals 18(6):816","journal-title":"Pharmaceuticals"},{"key":"6274_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.172988","volume":"874","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Xiang W, Jiang Y, Tian N, Wei Z, Wen X et al (2020) Withaferin A alleviates traumatic brain injury induced secondary brain injury via suppressing apoptosis in endothelia cells and modulating activation in the microglia. Eur J Pharmacol 874","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"6274_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112990","volume":"23","author":"S Merighi","year":"2022","unstructured":"Merighi S, Nigro M, Travagli A, Gessi S (2022) Microglia and Alzheimer\u2019s disease. Int J Mol Sci 23(21)","journal-title":"Int J Mol Sci"},{"key":"6274_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109436","volume":"113","author":"L Wang","year":"2022","unstructured":"Wang L, Wang X, Deng L, Zhang H, He B, Cao W et al (2022) Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders. Int Immunopharmacol 113","journal-title":"Int Immunopharmacol"},{"key":"6274_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701282","volume":"12","author":"H Bai","year":"2021","unstructured":"Bai H, Zhang Q (2021) Activation of NLRP3 inflammasome and onset of Alzheimer\u2019s disease. Front Immunol 12","journal-title":"Front Immunol"},{"key":"6274_CR60","doi-asserted-by":"crossref","unstructured":"Shukla SD. Molecular and therapeutic insights into Withania somnifera (Ashwagandha) for cognition and neuroprotection. Acad Biol. 2025;3(4).","DOI":"10.20935\/AcadBiol7925"},{"issue":"6","key":"6274_CR61","volume":"13","author":"V Lerose","year":"2024","unstructured":"Lerose V, Ponticelli M, Benedetto N, Carlucci V, Lela L, Tzvetkov NT et al (2024) Withania somnifera (L.) Dunal, a potential source of phytochemicals for treating neurodegenerative diseases: a systematic review. Plants (Basel) 13(6)","journal-title":"Plants (Basel)"},{"issue":"5","key":"6274_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051017","volume":"12","author":"PS Mishra","year":"2024","unstructured":"Mishra PS, Phaneuf D, Boutej H, Picher-Martel V, Dupre N, Kriz J et al (2024) Inhibition of NF-\u03baB with an analog of Withaferin-A restores TDP-43 homeostasis and proteome profiles in a model of sporadic ALS. Biomedicines 12(5)","journal-title":"Biomedicines"},{"issue":"8","key":"6274_CR63","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/ph14080765","volume":"14","author":"M Janowski","year":"2021","unstructured":"Janowski M, Milewska M, Zare P, P\u0119kowska A (2021) Chromatin alterations in neurological disorders and strategies of (Epi) genome rescue. Pharmaceuticals 14(8):765","journal-title":"Pharmaceuticals"},{"key":"6274_CR64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.conb.2020.04.001","volume":"63","author":"H Vitet","year":"2020","unstructured":"Vitet H, Brandt V, Saudou F (2020) Traffic signaling: new functions of huntingtin and axonal transport in neurological disease. Curr Opin Neurobiol 63:122\u2013130","journal-title":"Curr Opin Neurobiol"},{"issue":"1","key":"6274_CR65","first-page":"20","volume":"28","author":"C Cepeda","year":"2022","unstructured":"Cepeda C, Levine MS (2022) Synaptic dysfunction in Huntington\u2019s disease: lessons from genetic animal models. Neurosci 28(1):20\u201340","journal-title":"Neurosci"},{"issue":"6","key":"6274_CR66","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biomedicines10061432","volume":"10","author":"A Jurcau","year":"2022","unstructured":"Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington\u2019s disease. Biomedicines 10(6):1432","journal-title":"Biomedicines"},{"issue":"8","key":"6274_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087221","volume":"24","author":"A Tassone","year":"2023","unstructured":"Tassone A, Meringolo M, Ponterio G, Bonsi P, Schirinzi T, Martella G (2023) Mitochondrial bioenergy in neurodegenerative disease: Huntington and Parkinson. Int J Mol Sci 24(8)","journal-title":"Int J Mol Sci"},{"key":"6274_CR68","doi-asserted-by":"publisher","first-page":"611735","DOI":"10.3389\/fcell.2020.611735","volume":"8","author":"M Czeredys","year":"2020","unstructured":"Czeredys M (2020) Dysregulation of neuronal calcium signaling via store-operated channels in Huntington\u2019s disease. Front Cell Dev Biol 8:611735","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6274_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3233\/JHD-200429","volume":"10","author":"DG Monckton","year":"2021","unstructured":"Monckton DG (2021) The contribution of somatic expansion of the CAG repeat to symptomatic development in Huntington\u2019s disease: a historical perspective. J Huntingtons Dis 10(1):7\u201333","journal-title":"J Huntingtons Dis"},{"key":"6274_CR70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12703\/r\/10-77","volume":"10","author":"J Kaye","year":"2021","unstructured":"Kaye J, Reisine T, Finkbeiner S (2021) Huntington\u2019s disease mouse models: unraveling the pathology caused by CAG repeat expansion. Fac Rev 10:77","journal-title":"Fac Rev"},{"issue":"2","key":"6274_CR71","first-page":"129","volume":"5","author":"O Eje","year":"2023","unstructured":"Eje O, Ogbonna CV, Onoyima CS, Nduka FO (2023) Huntington disease: mechanism of pathogenesis and recent developments in its therapeutic strategies: a review. J Chem Rev 5(2):129\u2013142","journal-title":"J Chem Rev"},{"issue":"1","key":"6274_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41582-025-01159-7","volume":"22","author":"J Donaldson","year":"2026","unstructured":"Donaldson J, Hensman Moss D, Ciosi M, Usdin K, Balmus G, Monckton DG et al (2026) Huntington disease: somatic expansion, pathobiology and therapeutics. Nat Rev Neurol 22(1):5\u201321","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"6274_CR73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JHD-200427","volume":"10","author":"EP Hong","year":"2021","unstructured":"Hong EP, MacDonald ME, Wheeler VC, Jones L, Holmans P, Orth M et al (2021) Huntington\u2019s disease pathogenesis: two sequential components. J Huntingtons Dis 10(1):35\u201351","journal-title":"J Huntingtons Dis"},{"key":"6274_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2025.08.005","author":"J Legleiter","year":"2025","unstructured":"Legleiter J (2025) Membranes as targets and modifiers of mutant huntingtin aggregation. Trends Biochem Sci. https:\/\/doi.org\/10.1016\/j.tibs.2025.08.005","journal-title":"Trends Biochem Sci"},{"issue":"31","key":"6274_CR75","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.2174\/0929867326666190621101909","volume":"27","author":"E Tellone","year":"2020","unstructured":"Tellone E, Galtieri A, Ficarra S (2020) Reviewing biochemical implications of normal and mutated Huntingtin in Huntington\u2019s disease. Curr Med Chem 27(31):5137\u20135158","journal-title":"Curr Med Chem"},{"issue":"2","key":"6274_CR76","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41418-021-00914-9","volume":"29","author":"R Iennaco","year":"2022","unstructured":"Iennaco R, Formenti G, Trovesi C, Rossi RL, Zuccato C, Lischetti T et al (2022) The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities. Cell Death Differ 29(2):293\u2013305","journal-title":"Cell Death Differ"},{"issue":"7","key":"6274_CR77","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/ijms25073845","volume":"25","author":"H Tong","year":"2024","unstructured":"Tong H, Yang T, Xu S, Li X, Liu L, Zhou G et al (2024) Huntington\u2019s disease: complex pathogenesis and therapeutic strategies. Int J Mol Sci 25(7):3845","journal-title":"Int J Mol Sci"},{"key":"6274_CR78","doi-asserted-by":"crossref","unstructured":"Khan A, Abd Elaleem KG, Elsharief AA, Imran M, Ali YH, Saeed IK, et al. Exploration of mechanism of Withania somnifera (L.) dunal in the treatment of Huntington disease: a network pharmacology approaches integrated with molecular docking and dynamics. Orient J Chem. 2025;41(4).","DOI":"10.13005\/ojc\/410405"},{"issue":"9","key":"6274_CR79","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.3390\/ijms21093289","volume":"21","author":"HR Yun","year":"2020","unstructured":"Yun HR, Jo YH, Kim J, Shin Y, Kim SS, Choi TG (2020) Roles of autophagy in oxidative stress. Int J Mol Sci 21(9):3289","journal-title":"Int J Mol Sci"},{"issue":"15","key":"6274_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152262","volume":"11","author":"L G\u00f3mez-Virgilio","year":"2022","unstructured":"G\u00f3mez-Virgilio L, Silva-Lucero MdelC, Flores-Morelos DS, Gallardo-Nieto J, Lopez-Toledo G, Abarca-Fernandez AM et al (2022) Autophagy: a key regulator of homeostasis and disease: an overview of molecular mechanisms and modulators. Cells 11(15)","journal-title":"Cells"},{"issue":"10","key":"6274_CR81","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Yao S, Yang H, Liu S, Wang Y (2023) Autophagy: regulator of cell death. Cell Death Dis 14(10):648","journal-title":"Cell Death Dis"},{"issue":"9","key":"6274_CR82","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1007\/s12035-022-02897-1","volume":"59","author":"S Sahoo","year":"2022","unstructured":"Sahoo S, Padhy AA, Kumari V, Mishra P (2022) Role of ubiquitin\u2013proteasome and autophagy-lysosome pathways in \u03b1-synuclein aggregate clearance. Mol Neurobiol 59(9):5379\u20135407","journal-title":"Mol Neurobiol"},{"key":"6274_CR83","unstructured":"Rissardo JP, Caprara ALF. Protein aggregation and proteostasis failure in neurodegenerative diseases: mechanisms, structural insights, and therapeutic strategies. 2025;"},{"issue":"3","key":"6274_CR84","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/1871527322666230327092855","volume":"23","author":"L Kapil","year":"2024","unstructured":"Kapil L, Kumar V, Kaur S, Sharma D, Singh C, Singh A (2024) Role of autophagy and mitophagy in neurodegenerative disorders. CNS Neurol Disord Targets-CNS Neurol Disord 23(3):367\u2013383","journal-title":"CNS Neurol Disord Targets-CNS Neurol Disord"},{"issue":"23","key":"6274_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238974","volume":"21","author":"T Ichimiya","year":"2020","unstructured":"Ichimiya T, Yamakawa T, Hirano T, Yokoyama Y, Hayashi Y, Hirayama D et al (2020) Autophagy and autophagy-related diseases: a review. Int J Mol Sci 21(23)","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6274_CR86","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/15548627.2021.1936359","volume":"18","author":"M Kocak","year":"2022","unstructured":"Kocak M, Ezazi Erdi S, Jorba G, Maestro I, Farr\u00e9s J, Kirkin V et al (2022) Targeting autophagy in disease: established and new strategies. Autophagy 18(3):473\u2013495","journal-title":"Autophagy"},{"issue":"4","key":"6274_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/jnc.15002","volume":"154","author":"O Corti","year":"2020","unstructured":"Corti O, Blomgren K, Poletti A, Beart PM (2020) Autophagy in neurodegeneration: new insights underpinning therapy for neurological diseases. J Neurochem 154(4):354\u2013371","journal-title":"J Neurochem"},{"issue":"9","key":"6274_CR88","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.3390\/ijms21093369","volume":"21","author":"H Park","year":"2020","unstructured":"Park H, Kang JH, Lee S (2020) Autophagy in neurodegenerative diseases: a hunter for aggregates. Int J Mol Sci 21(9):3369","journal-title":"Int J Mol Sci"},{"issue":"9","key":"6274_CR89","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/cells14090652","volume":"14","author":"D Luis-Ravelo","year":"2025","unstructured":"Luis-Ravelo D, Fumagallo-Reading F, Febles-Casquero A, Lopez-Fernandez J, Marcellino DJ, Gonzalez-Hernandez T (2025) Dopamine receptor D3 induces transient, mTORC1-dependent autophagy that becomes persistent, AMPK-mediated, and neuroprotective in experimental models of Huntington\u2019s disease. Cells 14(9):652","journal-title":"Cells"},{"key":"6274_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1274727","volume":"17","author":"S Yu","year":"2023","unstructured":"Yu S, Liao J, Lin X, Luo Y, Lu G (2023) Crucial role of autophagy in propofol-treated neurological diseases: a comprehensive review. Front Cell Neurosci 17","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"6274_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010103","volume":"13","author":"C Li\u00e9nard","year":"2024","unstructured":"Li\u00e9nard C, Pintart A, Bomont P (2024) Neuronal autophagy: regulations and implications in health and disease. Cells 13(1)","journal-title":"Cells"},{"issue":"3","key":"6274_CR92","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12264-023-01120-y","volume":"40","author":"YY Li","year":"2024","unstructured":"Li YY, Qin ZH, Sheng R (2024) The multiple roles of autophagy in neural function and diseases. Neurosci Bull 40(3):363\u2013382","journal-title":"Neurosci Bull"},{"issue":"4","key":"6274_CR93","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00018-020-03667-9","volume":"78","author":"W Xu","year":"2021","unstructured":"Xu W, Ocak U, Gao L, Tu S, Lenahan CJ, Zhang J et al (2021) Selective autophagy as a therapeutic target for neurological diseases. Cell Mol Life Sci 78(4):1369\u20131392","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"6274_CR94","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s12013-024-01581-6","volume":"83","author":"M Shukla","year":"2025","unstructured":"Shukla M, Narayan M (2025) Proteostasis and its role in disease development. Cell Biochem Biophys 83(2):1725\u20131741","journal-title":"Cell Biochem Biophys"},{"key":"6274_CR95","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5497046","author":"A H\u00f6hn","year":"2020","unstructured":"H\u00f6hn A, Tramutola A, Cascella R (2020) Proteostasis failure in neurodegenerative diseases: focus on oxidative stress. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2020\/5497046","journal-title":"Oxid Med Cell Longev"},{"key":"6274_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00264","volume":"14","author":"EN Lottes","year":"2020","unstructured":"Lottes EN, Cox DN (2020) Homeostatic roles of the proteostasis network in dendrites. Front Cell Neurosci 14","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"6274_CR97","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tcb.2025.01.002","volume":"35","author":"SA Wu","year":"2025","unstructured":"Wu SA, Li ZJ, Qi L (2025) Endoplasmic reticulum (ER) protein degradation by ER-associated degradation and ER-phagy. Trends Cell Biol 35(7):576\u2013591","journal-title":"Trends Cell Biol"},{"key":"6274_CR98","doi-asserted-by":"publisher","first-page":"575608","DOI":"10.3389\/fmolb.2020.575608","volume":"7","author":"N Gariballa","year":"2020","unstructured":"Gariballa N, Ali BR (2020) Endoplasmic reticulum associated protein degradation (ERAD) in the pathology of diseases related to TGF\u03b2 signaling pathway: future therapeutic perspectives. Front Mol Biosci 7:575608","journal-title":"Front Mol Biosci"},{"issue":"12","key":"6274_CR99","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041247","volume":"14","author":"L Krshnan","year":"2022","unstructured":"Krshnan L, van de Weijer ML, Carvalho P (2022) Endoplasmic reticulum\u2013associated protein degradation. Cold Spring Harb Perspect Biol 14(12)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6274_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2021.112587","volume":"157","author":"R Fan","year":"2021","unstructured":"Fan R, Chen J, Gao X, Zhang Q (2021) Neurodevelopmental toxicity of alumina nanoparticles to zebrafish larvae: toxic effects of particle sizes and ions. Food Chem Toxicol 157","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"6274_CR101","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/carcin\/bgaa009","volume":"41","author":"SH Kim","year":"2020","unstructured":"Kim SH, Hahm ER, Singh KB, Shiva S, Stewart-Ornstein J, Singh SV (2020) RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells. Carcinogenesis 41(6):778\u2013789","journal-title":"Carcinogenesis"},{"issue":"1","key":"6274_CR102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1039\/C9MD00296K","volume":"11","author":"M Dom","year":"2020","unstructured":"Dom M, Vanden Berghe W, Van Ostade X (2020) Broad-spectrum antitumor properties of withaferin A: a proteomic perspective. RSC Med Chem 11(1):30\u201350","journal-title":"RSC Med Chem"},{"key":"6274_CR103","doi-asserted-by":"crossref","unstructured":"Moyano P, Sola E, Naval MV, Guerra-Men\u00e9ndez L, Fernandez MD la C, Del Pino J. Neurodegenerative proteinopathies induced by environmental pollutants: heat shock proteins and proteasome as promising therapeutic tools. Pharmaceutics. 2023;15(8):2048.","DOI":"10.3390\/pharmaceutics15082048"},{"key":"6274_CR104","doi-asserted-by":"crossref","unstructured":"Moyano-Cires Ivanoff PV, Sola Vendrell E, Naval L\u00f3pez MV, Guerra Men\u00e9ndez L, Fern\u00e1ndez Fern\u00e1ndez MDLC, Pino Sans J Del. Neurodegenerative proteinopathies induced by environmental pollutants: heat shock proteins and proteasome as promising therapeutic tools. 2023;","DOI":"10.3390\/pharmaceutics15082048"},{"issue":"10","key":"6274_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23154","volume":"36","author":"L Zhang","year":"2022","unstructured":"Zhang L, Shi Y, Yan M, Zhang G (2022) Modulatory action of withaferin-A on oxidative damage through regulation of inflammatory mediators and apoptosis via PI3K\/AKT signaling pathway in high cholesterol-induced atherosclerosis in experimental rats. J Biochem Mol Toxicol 36(10)","journal-title":"J Biochem Mol Toxicol"},{"issue":"9","key":"6274_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090333","volume":"8","author":"N Akhtar","year":"2020","unstructured":"Akhtar N, Baig MW, Haq I, Rajeeve V, Cutillas PR (2020) Withanolide metabolites inhibit PI3K\/AKT and MAPK pro-survival pathways and induce apoptosis in acute myeloid leukemia cells. Biomedicines 8(9)","journal-title":"Biomedicines"},{"issue":"1","key":"6274_CR107","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/ijms25010367","volume":"25","author":"N Vilaboa","year":"2023","unstructured":"Vilaboa N, Voellmy R (2023) Withaferin A and celastrol overwhelm proteostasis. Int J Mol Sci 25(1):367","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6274_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116089","volume":"23","author":"L G\u00f3mez-Jaramillo","year":"2022","unstructured":"G\u00f3mez-Jaramillo L, Cano-Cano F, Gonz\u00e1lez-Montelongo M, Campos-Caro A, Aguilar-Diosdado M, Arroba AI (2022) A new perspective on Huntington\u2019s disease: how a neurological disorder influences the peripheral tissues. Int J Mol Sci 23(11)","journal-title":"Int J Mol Sci"},{"key":"6274_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603594","volume":"11","author":"G Du","year":"2021","unstructured":"Du G, Dong W, Yang Q, Yu X, Ma J, Gu W et al (2021) Altered gut microbiota related to inflammatory responses in patients with Huntington\u2019s disease. Front Immunol 11","journal-title":"Front Immunol"},{"key":"6274_CR110","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molimm.2025.02.003","volume":"179","author":"JN Fung","year":"2025","unstructured":"Fung JN, Lee JD, Adam R, O\u2019Sullivan JD, Woodruff TM (2025) Peripheral and central elevation of IL-8 in patients with Huntington\u2019s disease. Mol Immunol 179:84\u201393","journal-title":"Mol Immunol"},{"key":"6274_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1374365","volume":"15","author":"JQ Xia","year":"2024","unstructured":"Xia JQ, Cheng YF, Zhang SR, Ma YZ, Fu JJ, Yang TM et al (2024) The characteristic and prognostic role of blood inflammatory markers in patients with Huntington\u2019s disease from China. Front Neurol 15","journal-title":"Front Neurol"},{"key":"6274_CR112","doi-asserted-by":"publisher","first-page":"103450","DOI":"10.1016\/j.nicl.2023.103450","volume":"39","author":"NA van de Zande","year":"2023","unstructured":"van de Zande NA, Bulk M, Najac C, van der Weerd L, de Bresser J, Lewerenz J et al (2023) Study protocol of IMAGINE-HD: imaging iron accumulation and neuroinflammation with 7T-MRI+ CSF in Huntington\u2019s disease. NeuroImage Clin 39:103450","journal-title":"NeuroImage Clin"},{"issue":"5","key":"6274_CR113","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mdc3.70010","volume":"12","author":"M Farag","year":"2025","unstructured":"Farag M, Knights H, Scahill RI, McColgan P, Estevez\u2010Fraga C (2025) Neuroimaging techniques in Huntington\u2019s disease: a critical review. Mov Disord Clin Pract 12(5):561\u2013576","journal-title":"Mov Disord Clin Pract"},{"issue":"21","key":"6274_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111787","volume":"25","author":"X Li","year":"2024","unstructured":"Li X, Tong H, Xu S, Zhou G, Yang T, Yin S et al (2024) Neuroinflammatory proteins in Huntington\u2019s disease: insights into mechanisms, diagnosis, and therapeutic implications. Int J Mol Sci 25(21)","journal-title":"Int J Mol Sci"},{"issue":"12","key":"6274_CR115","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.tips.2020.09.011","volume":"41","author":"L Gaetani","year":"2020","unstructured":"Gaetani L, Paoletti FP, Bellomo G, Mancini A, Simoni S, Di Filippo M et al (2020) CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment. Trends Pharmacol Sci 41(12):1023\u20131037","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"6274_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/cells14010054","volume":"14","author":"L M\u00fcller","year":"2025","unstructured":"M\u00fcller L, Di Benedetto S, M\u00fcller V (2025) From homeostasis to neuroinflammation: insights into cellular and molecular interactions and network dynamics. Cells 14(1)","journal-title":"Cells"},{"issue":"3","key":"6274_CR117","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/18796397251338207","volume":"14","author":"A Blusch","year":"2025","unstructured":"Blusch A, Bj\u00f6rkqvist M (2025) Neuroinflammation in Huntington\u2019s disease: causes, consequences, and treatment strategies. J Huntingtons Dis 14(3):258\u2013269","journal-title":"J Huntingtons Dis"},{"key":"6274_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088124","volume":"13","author":"Q Jia","year":"2022","unstructured":"Jia Q, Li S, Li XJ, Yin P (2022) Neuroinflammation in Huntington\u2019s disease: from animal models to clinical therapeutics. Front Immunol 13","journal-title":"Front Immunol"},{"issue":"3","key":"6274_CR119","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/18796397251330144","volume":"14","author":"M Abedrabbo","year":"2025","unstructured":"Abedrabbo M, Kazemian P, Connolly C, Leavitt BR (2025) Emerging roles of microglia and neuroinflammation in Huntington\u2019s disease: from pathophysiology to clinical trials. J Huntingtons Dis 14(3):241\u2013257","journal-title":"J Huntingtons Dis"},{"issue":"15","key":"6274_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158363","volume":"23","author":"E Paldino","year":"2022","unstructured":"Paldino E, Fusco FR (2022) Emerging role of NLRP3 inflammasome\/pyroptosis in Huntington\u2019s disease. Int J Mol Sci 23(15)","journal-title":"Int J Mol Sci"},{"key":"6274_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.643254","volume":"12","author":"JA Holbrook","year":"2021","unstructured":"Holbrook JA, Jarosz-Griffiths HH, Caseley E, Lara-Reyna S, Poulter JA, Williams-Gray CH et al (2021) Neurodegenerative disease and the NLRP3 inflammasome. Front Pharmacol 12","journal-title":"Front Pharmacol"},{"issue":"4","key":"6274_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11040999","volume":"11","author":"A Chiarini","year":"2023","unstructured":"Chiarini A, Gui L, Viviani C, Armato U, Dal Pr\u00e0 I (2023) NLRP3 inflammasome\u2019s activation in acute and chronic brain diseases\u2014an update on pathogenetic mechanisms and therapeutic perspectives with respect to other inflammasomes. Biomedicines 11(4)","journal-title":"Biomedicines"},{"issue":"1","key":"6274_CR123","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10020-024-00917-5","volume":"30","author":"ME Noureldeen","year":"2024","unstructured":"Noureldeen ME, Shahin NN, Amin HAA, El-Sawalhi MM, Ghaiad HR (2024) Parthenolide ameliorates 3-nitropropionic acid-induced Huntington\u2019s disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting. Mol Med 30(1):158","journal-title":"Mol Med"},{"issue":"2","key":"6274_CR124","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/ph18020248","volume":"18","author":"AM Mohmmed Hegab","year":"2025","unstructured":"Mohmmed Hegab AM, Hassanin SO, Mekky RH, Abuzahrah SS, Hamza AA, Talaat IM et al (2025) Withania somnifera ameliorates doxorubicin-induced nephrotoxicity and potentiates its therapeutic efficacy targeting SIRT1\/Nrf2, oxidative stress, inflammation, and apoptosis. Pharmaceuticals 18(2):248","journal-title":"Pharmaceuticals"},{"issue":"10","key":"6274_CR125","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/biomedicines9101449","volume":"9","author":"JW Lee","year":"2021","unstructured":"Lee JW, Chun W, Lee HJ, Kim SM, Min JH, Kim DY et al (2021) The role of microglia in the development of neurodegenerative diseases. Biomedicines 9(10):1449","journal-title":"Biomedicines"},{"key":"6274_CR126","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","volume":"71","author":"T Alqahtani","year":"2023","unstructured":"Alqahtani T, Deore SL, Kide AA, Shende BA, Sharma R, Chakole RD et al (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and amyotrophic lateral sclerosis-an updated review. Mitochondrion 71:83\u201392","journal-title":"Mitochondrion"},{"issue":"2","key":"6274_CR127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/antiox12020517","volume":"12","author":"EO Olufunmilayo","year":"2023","unstructured":"Olufunmilayo EO, Gerke-Duncan MB, Holsinger RMD (2023) Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants 12(2):517","journal-title":"Antioxidants"},{"issue":"1","key":"6274_CR128","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/pharmaceutics18010118","volume":"18","author":"J Bernatoniene","year":"2026","unstructured":"Bernatoniene J, Kopustinskiene DM, Casale R, Medoro A, Davinelli S, Saso L et al (2026) Nrf2 modulation by natural compounds in aging, neurodegeneration, and neuropathic pain. Pharmaceutics 18(1):118","journal-title":"Pharmaceutics"},{"key":"6274_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2026.1731771","volume":"20","author":"Y Pang","year":"2026","unstructured":"Pang Y, Yang J, Liu J, Xie Z, Wang J (2026) Metabolic interactions in the brain: the crucial roles of neurons, astrocytes, and microglia in health and disease. Front Neurosci 20","journal-title":"Front Neurosci"},{"issue":"6","key":"6274_CR130","first-page":"1308","volume":"18","author":"ZX Zhou","year":"2022","unstructured":"Zhou ZX, Cui Q, Zhang YM, Yang JX, Xiang WJ, Tian N et al (2022) Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage. Neural Regen Res 18(6):1308","journal-title":"Neural Regen Res"},{"issue":"2","key":"6274_CR131","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/ijms23020780","volume":"23","author":"S Maity","year":"2022","unstructured":"Maity S, Komal P, Kumar V, Saxena A, Tungekar A, Chandrasekar V (2022) Impact of ER stress and ER-mitochondrial crosstalk in Huntington\u2019s disease. Int J Mol Sci 23(2):780","journal-title":"Int J Mol Sci"},{"issue":"14","key":"6274_CR132","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.2174\/1389450122666210224105945","volume":"22","author":"A Sharma","year":"2021","unstructured":"Sharma A, Behl T, Sharma L, Aelya L, Bungau S (2021) Mitochondrial dysfunction in Huntington\u2019s disease: pathogenesis and therapeutic opportunities. Curr Drug Targets 22(14):1637\u20131667","journal-title":"Curr Drug Targets"},{"issue":"9","key":"6274_CR133","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awab473","volume":"145","author":"K Pircs","year":"2022","unstructured":"Pircs K, Drouin-Ouellet J, Horv\u00e1th V, Gil J, Rezeli M, Garza R et al (2022) Distinct subcellular autophagy impairments in induced neurons from patients with Huntington\u2019s disease. Brain 145(9):3035\u20133057","journal-title":"Brain"},{"issue":"4","key":"6274_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/life15040577","volume":"15","author":"F D\u2019Egidio","year":"2025","unstructured":"D\u2019Egidio F, Qosja E, Ammannito F, Topi S, d\u2019Angelo M, Cimini A et al (2025) Antioxidant and anti-inflammatory defenses in Huntington\u2019s disease: roles of NRF2 and PGC-1\u03b1, and therapeutic strategies. Life 15(4)","journal-title":"Life"},{"key":"6274_CR135","unstructured":"Chenh HM. Investigating the neuroprotective properties of Withania somnifera. Adelphi University; 2025."},{"issue":"1","key":"6274_CR136","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s12276-021-00556-4","volume":"53","author":"SM Son","year":"2021","unstructured":"Son SM, Park SJ, Fernandez-Estevez M, Rubinsztein DC (2021) Autophagy regulation by acetylation\u2014implications for neurodegenerative diseases. Exp Mol Med 53(1):30\u201341","journal-title":"Exp Mol Med"},{"issue":"14","key":"6274_CR137","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.2174\/0929867327666200705225821","volume":"28","author":"A Pogoda","year":"2021","unstructured":"Pogoda A, Chmielewska N, Maciejak P, Szyndler J (2021) Transcriptional dysregulation in Huntington\u2019s disease: the role in pathogenesis and potency for pharmacological targeting. Curr Med Chem 28(14):2783\u20132806","journal-title":"Curr Med Chem"},{"issue":"11","key":"6274_CR138","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41593-022-01185-4","volume":"25","author":"YM Oh","year":"2022","unstructured":"Oh YM, Lee SW, Kim WK, Chen S, Church VA, Cates K et al (2022) Age-related Huntington\u2019s disease progression modeled in directly reprogrammed patient-derived striatal neurons highlights impaired autophagy. Nat Neurosci 25(11):1420\u20131433","journal-title":"Nat Neurosci"},{"issue":"7","key":"6274_CR139","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cells10071565","volume":"10","author":"R Monk","year":"2021","unstructured":"Monk R, Connor B (2021) Cell reprogramming to model Huntington\u2019s disease: a comprehensive review. Cells 10(7):1565","journal-title":"Cells"},{"issue":"5","key":"6274_CR140","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2024.2348738","volume":"33","author":"SE Field","year":"2024","unstructured":"Field SE, Curle AJ, Barker RA (2024) Inflammation and Huntington\u2019s disease\u2013a neglected therapeutic target? Expert Opin Investig Drugs 33(5):451\u2013467","journal-title":"Expert Opin Investig Drugs"},{"key":"6274_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1690170","volume":"19","author":"Y Fan","year":"2025","unstructured":"Fan Y, Lian X, Ren X, Ren L, Liu C, Meng Y et al (2025) The multi-pathway treatment of flavonoids as natural compounds in neurological diseases: achievements, limitations, and prospects. Front Neurosci 19","journal-title":"Front Neurosci"},{"issue":"10","key":"6274_CR142","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70053","volume":"30","author":"AA Bhat","year":"2024","unstructured":"Bhat AA, Moglad E, Afzal M, Thapa R, Almalki WH, Kazmi I et al (2024) Therapeutic approaches targeting aging and cellular senescence in Huntington\u2019s disease. CNS Neurosci Ther 30(10)","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"6274_CR143","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/01635581.2023.2183546","volume":"75","author":"MA Islam","year":"2023","unstructured":"Islam MA, Medha MM, Nahar AU, Al Fahad MA, Siraj MA, Seidel V (2023) Cancer protective role of selected dietary polyphenols via modulating Keap1\/Nrf2\/ARE and interconnected signaling pathways. Nutr Cancer 75(4):1065\u20131102","journal-title":"Nutr Cancer"},{"key":"6274_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1103416","volume":"14","author":"J Qin","year":"2023","unstructured":"Qin J, Ma Z, Chen X, Shu S (2023) Microglia activation in central nervous system disorders: a review of recent mechanistic investigations and development efforts. Front Neurol 14","journal-title":"Front Neurol"},{"issue":"5","key":"6274_CR145","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s43440-025-00736-3","volume":"77","author":"X Chen","year":"2025","unstructured":"Chen X, Ma X, Hu X, Wang C, Zhang X, Yan C (2025) Mechanisms and potential therapeutic strategies of Withaferin A in breast cancer. Pharmacol Rep 77(5):1163\u20131176","journal-title":"Pharmacol Rep"},{"issue":"4","key":"6274_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint18040064","volume":"18","author":"A Aguilera-M\u00e9ndez","year":"2026","unstructured":"Aguilera-M\u00e9ndez A, Aguilera-Manuel K, Saavedra-Molina A, R\u00edos-Ch\u00e1vez P, Villafa\u00f1a S, Nieto-Aguilar R et al (2026) Alpha-lipoic acid and biotin in neurodegenerative diseases: convergent mechanistic insights from preclinical models to clinical perspectives. Neurol Int 18(4)","journal-title":"Neurol Int"},{"issue":"11","key":"6274_CR147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312524","volume":"19","author":"O Simoncik","year":"2024","unstructured":"Simoncik O, Tichy V, Durech M, Hernychova L, Trcka F, Uhrik L et al (2024) Direct activation of HSF1 by macromolecular crowding and misfolded proteins. PLoS One 19(11)","journal-title":"PLoS One"},{"key":"6274_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.phyplu.2026.100974","author":"R Chauhan","year":"2026","unstructured":"Chauhan R, Kondaveeti SB, Babu N, Pathak VM, Kaur D, Tuli HS et al (2026) Withaferin A: mechanisms of action, therapeutic efficacy, and clinical potential in gastrointestinal cancer treatment: a comprehensive review. Phytomed Plus. https:\/\/doi.org\/10.1016\/j.phyplu.2026.100974","journal-title":"Phytomed Plus"},{"key":"6274_CR149","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S422512","author":"Z Xing","year":"2023","unstructured":"Xing Z, Su A, Mi L, Zhang Y, He T, Qiu Y et al (2023) Withaferin A: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment-pharmacology and mechanisms. Drug Des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S422512","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"6274_CR150","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3233\/JHD-200425","volume":"9","author":"D Howland","year":"2020","unstructured":"Howland D, Ellederova Z, Aronin N, Fernau D, Gallagher J, Taylor A et al (2020) Large animal models of Huntington\u2019s disease: what we have learned and where we need to go next. J Huntington Dis 9(3):201\u2013216","journal-title":"J Huntington Dis"},{"issue":"5","key":"6274_CR151","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1124\/dmd.121.000455","volume":"50","author":"Y Xia","year":"2022","unstructured":"Xia Y, Yan M, Wang P, Hamada K, Yan N, Hao H et al (2022) Withaferin A in the treatment of liver diseases: progress and pharmacokinetic insights. Drug Metab Dispos 50(5):685\u2013693","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"6274_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27051476","volume":"27","author":"SJ Modi","year":"2022","unstructured":"Modi SJ, Tiwari A, Ghule C, Pawar S, Saste G, Jagtap S et al (2022) Pharmacokinetic study of withanosides and withanolides from Withania somnifera using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS\/MS). Molecules 27(5)","journal-title":"Molecules"},{"key":"6274_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1540237","volume":"16","author":"K Chutani","year":"2025","unstructured":"Chutani K, Rai N, Sardar A, Yadav A, Rai D, Raj A et al (2025) Fortified Withaferin A accelerates the transition from fibrovascular to bone remodeling phase during endochondral bone formation to promote ossification. Front Endocrinol (Lausanne) 16","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6274_CR154","doi-asserted-by":"publisher","first-page":"117957352210925","DOI":"10.1177\/11795735221092517","volume":"14","author":"MW Ferguson","year":"2022","unstructured":"Ferguson MW, Kennedy CJ, Palpagama TH, Waldvogel HJ, Faull RLM, Kwakowsky A (2022) Current and possible future therapeutic options for Huntington\u2019s disease. J Cent Nerv Syst Dis 14:11795735221092516","journal-title":"J Cent Nerv Syst Dis"},{"issue":"5","key":"6274_CR155","first-page":"162","volume":"16","author":"R Kurniawan","year":"2026","unstructured":"Kurniawan R, Ashari A, Saputra MY, Ahmadi P, Suhartati T (2026) The lapachol derivatives from Tabebuia aurea: distribution and cytotoxic evaluation against human cancer cells. J Appl Pharm Sci 16(5):162\u2013168","journal-title":"J Appl Pharm Sci"},{"issue":"6","key":"6274_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062146","volume":"21","author":"F Marxreiter","year":"2020","unstructured":"Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21(6)","journal-title":"Int J Mol Sci"},{"key":"6274_CR157","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2023.02.075","volume":"655","author":"D Kumar","year":"2023","unstructured":"Kumar D, Hasan GM, Islam A, Hassan MI (2023) Therapeutic targeting of Huntington\u2019s disease: Molecular and clinical approaches. Biochem Biophys Res Commun 655:18\u201324","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"6274_CR158","doi-asserted-by":"publisher","first-page":"369","DOI":"10.14802\/jmd.24140","volume":"17","author":"JH Shin","year":"2024","unstructured":"Shin JH, Yang HJ, Ahn JH, Jo S, Chung SJ, Lee JY et al (2024) Evidence-based review on symptomatic management of Huntington\u2019s disease. J Mov Disord 17(4):369","journal-title":"J Mov Disord"},{"issue":"23","key":"6274_CR159","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMc2300400","volume":"389","author":"P McColgan","year":"2023","unstructured":"McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G et al (2023) Tominersen in adults with manifest Huntington\u2019s disease. N Engl J Med 389(23):2203\u20132205","journal-title":"N Engl J Med"},{"key":"6274_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.151572","author":"HV Pour","year":"2026","unstructured":"Pour HV, Motamedi S, Mirzaei B, Fernandes CBL, Mourtaja H (2026) Alterations of brain-derived neurotrophic factor, nerve growth factor and neurotrophin-3 levels across biofluids and brain regions in Huntington\u2019s disease: a comprehensive systematic review, meta-analysis and meta-regression of human and rodent studies. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151572","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"6274_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121900","volume":"18","author":"NG Emek","year":"2025","unstructured":"Emek NG, Tan AM, Geva M, Fekete A, Abate C, Hayden MR (2025) Pridopidine, a potent and selective therapeutic sigma-1 receptor (S1R) agonist for treating neurodegenerative diseases. Pharmaceuticals (Basel) 18(12)","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"6274_CR162","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.4103\/1673-5374.360289","volume":"18","author":"A Jurcau","year":"2022","unstructured":"Jurcau A, Jurcau CM (2022) Mitochondria in Huntington\u2019s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies. Neural Regen Res 18(7):1472","journal-title":"Neural Regen Res"},{"key":"6274_CR163","doi-asserted-by":"publisher","DOI":"10.1039\/d5fo03139g","author":"S Zhang","year":"2025","unstructured":"Zhang S, Wu Z, Zhang S, Ru Y, Wang Q, Tong H et al (2025) The intricate microbial-gut-brain axis in Alzheimer\u2019s disease: a review of microbiota-targeted strategies. Food Funct. https:\/\/doi.org\/10.1039\/d5fo03139g","journal-title":"Food Funct"},{"key":"6274_CR164","doi-asserted-by":"crossref","unstructured":"Ahmad Z, Shareen, Ganie IB, Firdaus F, Ramakrishnan M, Shahzad A, et al. Enhancing withanolide production in the Withania species: advances in in vitro culture and synthetic biology approaches. Plants. 2024;13(15):2171.","DOI":"10.3390\/plants13152171"},{"issue":"11","key":"6274_CR165","volume":"20","author":"J Dai","year":"2025","unstructured":"Dai J, Zhang S, Shi J, Zhu J (2025) Targeting mitochondrial dysfunction for the prevention and treatment of non-alcoholic fatty liver disease. Nat Prod Commun 20(11)","journal-title":"Nat Prod Commun"},{"key":"6274_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1758356","volume":"17","author":"H Wang","year":"2026","unstructured":"Wang H, Li F, Wang H, Tian Z, Fan H, Shi Z (2026) Resveratrol and the neuroinflammation axis in Alzheimer\u2019s disease, Parkinson\u2019s disease, multiple sclerosis, and cerebral ischemia. Front Immunol 17","journal-title":"Front Immunol"},{"issue":"12","key":"6274_CR167","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1080\/10286020.2024.2371040","volume":"26","author":"Z Hui","year":"2024","unstructured":"Hui Z, Lai-Fa W, Xue-Qin W, Ling D, Bin-Sheng H, Li JM (2024) Mechanisms and therapeutic potential of chinonin in nervous system diseases. J Asian Nat Prod Res 26(12):1405\u20131420","journal-title":"J Asian Nat Prod Res"},{"issue":"3","key":"6274_CR168","first-page":"29","volume":"15","author":"A Nikkhah","year":"2021","unstructured":"Nikkhah A (2021) A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran J Child Neurol 15(3):29","journal-title":"Iran J Child Neurol"},{"issue":"5","key":"6274_CR169","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/procel\/pwae042","volume":"16","author":"X Piao","year":"2025","unstructured":"Piao X, Li D, Liu H, Guo Q, Yu Y (2025) Advances in gene and cellular therapeutic approaches for Huntington\u2019s disease. Protein Cell 16(5):307\u2013337","journal-title":"Protein Cell"},{"issue":"3","key":"6274_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00557","volume":"22","author":"CY Cheng","year":"2025","unstructured":"Cheng CY, Chen KP, Tseng TS, Hua KF, Ju TC (2025) The therapeutic potential of (R)-carvedilol in Huntington\u2019s disease through enhancement of autophagy-lysosomal pathway via GSK-3\u03b2 inhibition. Neurotherapeutics 22(3)","journal-title":"Neurotherapeutics"},{"key":"6274_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1734880","volume":"17","author":"Z Wang","year":"2026","unstructured":"Wang Z, Wang L, Ji M, Lou J, Yuan Y, Cui Y et al (2026) Mitochondrial dysfunction in immune cells during the perioperative period: mechanisms, emerging therapeutic strategies, and implications for multi-organ protection. Front Immunol 17","journal-title":"Front Immunol"},{"issue":"1","key":"6274_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47010008","volume":"47","author":"ME Kim","year":"2024","unstructured":"Kim ME, Lee JS (2024) Mechanisms and emerging regulators of neuroinflammation: exploring new therapeutic strategies for neurological disorders. Curr Issues Mol Biol 47(1)","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"6274_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15020124","volume":"15","author":"EP de Lima","year":"2025","unstructured":"de Lima EP, Laurindo LF, Catharin VCS, Direito R, Tanaka M, Jasmin Santos German I et al (2025) Polyphenols, alkaloids, and terpenoids against neurodegeneration: evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence. Metabolites 15(2)","journal-title":"Metabolites"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06274-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06274-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:02:30Z","timestamp":1792252950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06274-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":173,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6274"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06274-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"975"}}